Page last updated: 2024-11-10

l 663536

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MK-886: orally active leukotriene biosynthesis inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3651377
CHEMBL ID29097
CHEBI ID75390
SCHEMBL ID503001
MeSH IDM0168970

Synonyms (76)

Synonym
HMS3393N18
gtpl2655
NCGC00025106-01 ,
tocris-1311
LOPAC0_000774
CURATOR_000017
MLS001424151
1h-indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-alpha,alpha-dimethyl-5-(1-methylethyl)- [cas]
MLS000758280
smr000466278
mk 886
mk-886
1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(1-methylethyl)-1h-indole-2-propanoic acid
1h-indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(1-methylethyl)-
l-663,536
3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid
l 663536
nsc-736463
nsc736463
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1h-indol-2-yl]-2,2-dimethylpropanoic acid
118414-82-7
mk886
l-663536
HMS2051N18
chebi:75390 ,
CHEMBL29097 ,
3-[3-tert-butylsulfanyl-1-(4-chloro-benzyl)-5-isopropyl-1h-indol-2-yl]-2,2-dimethyl-propionic acid
3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1h-indol-2-yl)-2,2-dimethylpropanoic acid
cid_3651377
3-(1-(4-chlorobenzyl)-3-(tert-butylthio)-5-isopropyl-1h-indol-2-yl)-2,2-dimethylpropanoic acid
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
bdbm50006805
3-[3-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
NCGC00025106-02
3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-isopropyl-1h-indol-2-yl]-2,2-dimethylpropanoic acid
CCG-101053
unii-080626sq8c
080626sq8c ,
FT-0628956
S8236
1-(p-chlorobenzyl)-3-(t-butylthio)-alpha,alpha-dimethyl -5-(i-propyl)-indole-2-propanoic acid
3-[3-tert-butylsulfanyl-1-(4-chloro-benzyl)-5-isopropyl-1h-indoi-2-yl]-2,2-dimethyl-propionic acid
1-(p chlorobenzyl)-3-(t-butylthio)-alpha,alpha-dimethyl-5-(i-propyl)-indole-2-propanoic acid
AKOS022178156
AM808017
NC00303
mfcd00876710
1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]- a,a-dimethyl-5-(1-methylethyl)-1h-indole-2-propanoic acid
SCHEMBL503001
1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-?,?-dimethyl-5-(1-methylethyl)-1h-indole-2-propanoic acid
1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-.alpha.,.alpha.- dimethyl-5-(1-methylethyl)-1h-indole-2-propanoic acid
AC-31484
3-(1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid
cgs-81585
1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-.alpha.,.alpha.-dimethyl-5-(1-methylethyl)-1h-indole-2-propanoic acid
1h-indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-.alpha.,.alpha.-dimethyl-5-(1-methylethyl)-
DTXSID5041067
J328.555C ,
EX-A127
CS-5755
HY-14166
3-[3-(tert-butylsulfanyl)-1-[(4-chlorophenyl)methyl]-5-(propan-2-yl)-1h-indol-2-yl]-2,2-dimethylpropanoic acid
AS-74991
SR-01000076049-3
sr-01000076049
BCP06501
mk-886 (l-663,536)
Q27086912
SB19084
SDCCGSBI-0050752.P002
1h-indole-2-propanoic acid,1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-
HMS3742O07
qy7 ,
A893175
3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1h-indol-2-yl)-2,2-dimethylpropanoicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The data suggest that both COX inhibitors and 5-LOX inhibitors may be neuroprotective in vivo by suppressing toxic actions of microglia/macrophages, and that combinations of the two might have greater therapeutic potential than single inhibitors of either class."( Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity.
Klegeris, A; McGeer, PL,
)
0.13
" A marked decrease in the glutathione level of a majority of cells was observed after more toxic combination treatment."( Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Kuchárová, B; Mikeš, J; Mikešová, L; Vargová, J, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Such measurements, combined with bioavailability data from other species, may be useful for predicting biochemical activity in man."( Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Black, C; Brideau, C; Chan, C; Ford-Hutchinson, A; Frenette, R; Tagari, P, 1993
)
0.29
" In vivo PK studies in dogs demonstrate 55% oral bioavailability and an 7 h half-life."( Novel benzoxazole inhibitors of mPGES-1.
Berlioz, F; Demian, D; Hoffmaster, K; Kablaoui, N; Moore, WM; Nugent, RA; Patel, S; Shao, J; Vazquez, ML, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"25 or 0h oral dosing of the 5-lipoxygenase inhibitor, MK-886, but not when only one of these doses was given."( Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage.
Rainsford, KD, 1993
)
0.29
" Repeated aerosolization of leukotriene C4 (LTC4) to guinea-pigs produced leftward shift in their pulmonary resistance (RL) dose-response curves to inhaled acetylcholine (ACh) without increasing the maximum responses."( Role of leukotrienes in airway hyperresponsiveness in guinea-pigs.
Ishida, K; Schellenberg, RR; Thomson, RJ, 1993
)
0.29
" After daily intraperitoneal dosage the extract of mixed acetylboswellic acids (20 mg/kg) significantly reduced the clinical symptoms in guinea pigs with experimental autoimmune encephalomyelitis (EAE) between days 11 and 21."( Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis.
Ammon, HP; Metzger, G; Neu, IS; Safayhi, H; Vogel, U; Wehrmann, M; Wildfeuer, A, 1998
)
0.3
"5 g resting tensions, NOS inhibitors shifted the ACh dose-response curve to the right."( Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips.
Bani, D; Ciuffi, M; Failli, P; Franchi-Micheli, S; Mazzetti, L; Zilletti, L, 2000
)
0.31
" MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells."( Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.
Biswal, SS; Datta, K; Fischer, SM; Kehrer, JP; La, E; Thuillier, P; Vanden Heuvel, JP, 2001
)
0.31
" Nevertheless, vasopressin (AVP) release decreased in a dose-response manner in the early phase of sepsis."( Leukotriene synthesis inhibitor decreases vasopressin release in the early phase of sepsis.
Faccioli, LH; Martins, TF; Rocha, MJ; Sorgi, CA, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
leukotriene antagonistA drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
indolesAny compound containing an indole skeleton.
monocarboxylic acidAn oxoacid containing a single carboxy group.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.70790.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency3.98110.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency3.98110.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency45.71530.031637.5844354.8130AID504865; AID540327
TDP1 proteinHomo sapiens (human)Potency12.61080.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460; AID1468
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.31620.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency22.38720.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency32.46480.540617.639296.1227AID2528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902; AID924
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency15.84890.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
DNA polymerase betaHomo sapiens (human)Potency50.11870.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency17.78280.039816.784239.8107AID1454
tyrosine-protein kinase YesHomo sapiens (human)Potency48.73150.00005.018279.2586AID686947
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency89.12510.010323.856763.0957AID2662
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.03900.00798.23321,122.0200AID2546; AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency14.12540.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Integrin beta-3Homo sapiens (human)Potency31.62280.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency31.62280.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)2.22740.00102.030810.0000AID1057565; AID1153839; AID1239703; AID1267529; AID1272815; AID1357408; AID1357415; AID1478503; AID1484243; AID1759203; AID1759205; AID1800288; AID412944; AID413198; AID420629; AID453620; AID465970; AID578380; AID598669; AID620116; AID620118; AID637533; AID637535; AID688621; AID700864; AID703840; AID717377; AID721277; AID722473; AID733352
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)5.33670.00032.177410.0000AID1357417; AID1625261; AID412948
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)0.49000.00011.68479.3200AID1057567; AID1395141; AID413196; AID598671; AID6731; AID6734; AID700862
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)21.52000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)21.52000.00022.45859.9600AID1803986; AID1805801
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00462.018210.0000AID7092
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.505710.0000AID7212
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.497310.0000AID7212
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Arachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)IC50 (µMol)0.02500.00160.07630.5800AID1411795; AID1625260; AID405531; AID420623; AID465971; AID632155; AID632156; AID632157; AID632158; AID665660; AID7206; AID7212; AID721254
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.498810.0000AID7212
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.504610.0000AID7212
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)15.70250.00010.995010.0000AID1057565; AID1173017; AID413191
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.506510.0000AID7212
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.505710.0000AID7212
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Leukotriene C4 synthaseHomo sapiens (human)IC50 (µMol)3.00003.00004.00005.0000AID1902162
Macrophage-expressed gene 1 proteinHomo sapiens (human)IC50 (µMol)2.20000.21002.52409.1000AID1201316
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.02300.00010.507510.0000AID7212
Prostaglandin E synthase 2Homo sapiens (human)IC50 (µMol)1.60001.60002.10002.6000AID240920
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)1.05600.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)1.23700.006022.3670130.5170AID1914
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)11.22000.00304.11059.8200AID1803987
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)1.23700.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)Inhibition10.01750.03500.78251.5300AID7148; AID7150
Leukotriene C4 synthaseRattus norvegicus (Norway rat)Inhibition0.00300.00300.00300.0030AID101440
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (176)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
leukotriene production involved in inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
positive regulation of acute inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene biosynthetic processArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
lipoxygenase pathwayArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein homotrimerizationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular response to calcium ionArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular oxidant detoxificationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
leukotriene metabolic processLeukotriene C4 synthaseHomo sapiens (human)
leukotriene metabolic processLeukotriene C4 synthaseHomo sapiens (human)
long-chain fatty acid biosynthetic processLeukotriene C4 synthaseHomo sapiens (human)
cellular oxidant detoxificationLeukotriene C4 synthaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene C4 synthaseHomo sapiens (human)
adaptive immune responseMacrophage-expressed gene 1 proteinHomo sapiens (human)
dendritic cell antigen processing and presentationMacrophage-expressed gene 1 proteinHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigenMacrophage-expressed gene 1 proteinHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to Gram-negative bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
defense response to Gram-positive bacteriumMacrophage-expressed gene 1 proteinHomo sapiens (human)
transmembrane transportMacrophage-expressed gene 1 proteinHomo sapiens (human)
antibacterial innate immune responseMacrophage-expressed gene 1 proteinHomo sapiens (human)
lipid metabolic processProstaglandin E synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin E synthase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionProstaglandin E synthase 2Homo sapiens (human)
secretionProstaglandin E synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (57)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
arachidonate 5-lipoxygenase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme activator activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
identical protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein-containing complex bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
arachidonic acid bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione transferase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione peroxidase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene-C4 synthase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
leukotriene-C4 synthase activityLeukotriene C4 synthaseHomo sapiens (human)
protein bindingLeukotriene C4 synthaseHomo sapiens (human)
enzyme activator activityLeukotriene C4 synthaseHomo sapiens (human)
lipid bindingLeukotriene C4 synthaseHomo sapiens (human)
identical protein bindingLeukotriene C4 synthaseHomo sapiens (human)
glutathione peroxidase activityLeukotriene C4 synthaseHomo sapiens (human)
glutathione transferase activityLeukotriene C4 synthaseHomo sapiens (human)
wide pore channel activityMacrophage-expressed gene 1 proteinHomo sapiens (human)
DNA bindingProstaglandin E synthase 2Homo sapiens (human)
protein bindingProstaglandin E synthase 2Homo sapiens (human)
lyase activityProstaglandin E synthase 2Homo sapiens (human)
heme bindingProstaglandin E synthase 2Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityProstaglandin E synthase 2Homo sapiens (human)
glutathione bindingProstaglandin E synthase 2Homo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulum membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nuclear envelopeLeukotriene C4 synthaseHomo sapiens (human)
nuclear outer membraneLeukotriene C4 synthaseHomo sapiens (human)
endoplasmic reticulumLeukotriene C4 synthaseHomo sapiens (human)
endoplasmic reticulum membraneLeukotriene C4 synthaseHomo sapiens (human)
membraneLeukotriene C4 synthaseHomo sapiens (human)
nuclear membraneLeukotriene C4 synthaseHomo sapiens (human)
intracellular membrane-bounded organelleLeukotriene C4 synthaseHomo sapiens (human)
nuclear envelopeLeukotriene C4 synthaseHomo sapiens (human)
endoplasmic reticulumLeukotriene C4 synthaseHomo sapiens (human)
phagocytic vesicle membraneMacrophage-expressed gene 1 proteinHomo sapiens (human)
phagolysosome membraneMacrophage-expressed gene 1 proteinHomo sapiens (human)
extracellular regionMacrophage-expressed gene 1 proteinHomo sapiens (human)
cytoplasmic vesicleMacrophage-expressed gene 1 proteinHomo sapiens (human)
phagocytic vesicleMacrophage-expressed gene 1 proteinHomo sapiens (human)
Golgi membraneProstaglandin E synthase 2Homo sapiens (human)
extracellular regionProstaglandin E synthase 2Homo sapiens (human)
nucleusProstaglandin E synthase 2Homo sapiens (human)
mitochondrionProstaglandin E synthase 2Homo sapiens (human)
cytosolProstaglandin E synthase 2Homo sapiens (human)
azurophil granule lumenProstaglandin E synthase 2Homo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthase 2Homo sapiens (human)
mitochondrionProstaglandin E synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1057580Reduction of PGE2 biosynthesis in CD-1 mouse peritonitis model at 1 mg/kg, ip administered 30 mins prior to zymosan-challenge measured after 4 hrs by RIA (Rvb = 1.46 +/- 0.08 ng/ml)2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID1625261Inhibition of ovine COX-1 assessed as 12-HHT formation preincubated for 5 mins followed by addition of arachidonic acid as substrate measured after 5 mins by HPLC analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions.
AID620118Inhibition of human recombinant microsomal PGES-1 expressed in freestyle 293-f cells assessed as conversion of PGH2 to PGE2 after 15 mins by enzyme immunoassay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Novel human mPGES-1 inhibitors identified through structure-based virtual screening.
AID1448337Change in total alpha-tubulin levels in human QBI293 cells at 1 uM after 4 hrs by ELISA relative to control2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
AID1267529Inhibition of PGES-1 in human A549 cell microsomes using PGH2 as substrate assessed as suppression of interleukin-1beta-stimulated PGE2 production incubated for 15 mins post interleukin-1beta challenge for 72 hrs by RP-HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study.
AID453635Inhibition of mPGES1 in IL1-beta induced human A549 cells assessed as PGE2 production at 30 uM preincubated for 10 mins2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID420629Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as residual enzyme activity after 1 min by measuring PGE2 level using RP-HPLC method2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID637535Inhibition of mPGES-12012European journal of medicinal chemistry, Feb, Volume: 48Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
AID1057582Reduction of LTC4 formation in CD-1 mouse peritonitis model at 1 mg/kg, ip administered 30 mins prior to zymosan-challenge measured after 30 mins by EIA relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID1202856Inhibition of m-PGES1 in IL-1beta-induced human A549 cell microsomes assessed as reduction in 11beta-PGE2 production pre-incubated for 15 mins before PGH2 addition by UV detection based reverse-phase high-performance liquid chromatography2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Myxochelins target human 5-lipoxygenase.
AID596825Inhibition of human microsomal PGES1 in cell-free system assessed as inhibition of conversion of PGH2 to PGE2 at 10 uM by HPLC assay relative to control2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E₂ synthase-1 (mPGES-1).
AID632046Inhibition of FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production preincubated for 15 mins by ELISA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID89429The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS]1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID178502Compound was tested for in vivo inhibition against rat ionophore LTB4 formation1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1173017Inhibition of human recombinant COX2 in cell-free system by enzyme immunoassay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and PGE₂ production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells.
AID92724Compound was tested for in vitro inhibition against human whole blood1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1267530Inhibition of PGES-1 in human A549 cell microsomes using PGH2 as substrate assessed as remaining enzyme activity of interleukin-1beta-stimulated PGE2 production at 10 uM incubated for 15 mins post interleukin-1beta challenge for 72 hrs by RP-HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study.
AID578380Inhibition of mPGES-1 expressed in LPS-stimulated human A549 cells mitochondrial fraction assessed as conversion of PGH2 to PGE22011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold.
AID7148The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID1759200Cytotoxicity against human A549 cells assessed as cell viability incubated for 24 hrs in presence of IL-1beta by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E
AID6731Inhibition of Human 5-lipoxygenase1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
AID453620Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE22009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID598669Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1.
AID420627Inhibition of mPGES1 in IL1-beta treated human A549 cell microsomal membrane assessed as residual enzyme activity at 10 uM after 1 min by measuring PGE2 level using RP-HPLC method relative to control2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID688621Inhibition of mPGES1 in IL-1beta treated human A549 cell microsomal membrane assessed as inhibition of PGE2 formation incubated for 15 mins before addition of PGH2 by RP-HPLC method2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.
AID420623Binding affinity to FLAP2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID420624Inhibition of rat mPGES12009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID665659Inhibition of FLAP in A23187-stimulated human neutrophils assessed as 5-LO product formation at 10 uM preincubated for 15 mins measured after 10 mins relative to control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
AID733352Inhibition of microsomal PGES-1 (unknown origin)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
AID598671Inhibition of 5-lipoxygenase in A23187-stimulated human PMNL assessed as enzyme product formation preincubated 15 mins by RP-HPLC analysis in presence of exogenous arachidonic acid2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1.
AID721277Inhibition of human recombinant mPGES-1 using PGH2 as substrate incubated 20 mins prior to substrate addition measured after 30 secs by EIA2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel benzoxazole inhibitors of mPGES-1.
AID412942Inhibition of 5-LO in human PMNL cells at 10 uM relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1155609Antiinflammatory activity in zymosan-induced peritonitis CD1 mouse model assessed as suppression of LTB4 level at 1 mg/kg, ip administered 30 mins before challenge measured 30 mins post zymosan challenge relative to control v2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase.
AID665661Inhibition of human FLAP in cell-free system assessed as inhibition of 5-LO product formation at 10 uM preincubated for 15 mins measured after 10 mins relative to control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
AID1625260Antagonist activity at FLAP in human PMNC assessed as inhibition of A23187-induced LTB4 biosynthesis pre-incubated for 2 mins followed by addition of A23187 measured after 5 mins by radioimmunoassay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions.
AID1057572Inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli BL21 using arachidonic acid as substrate at 1 uM incubated 5 to 10 mins prior to substrate addition measured after 10 mins by HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID632157Inhibition of FLAP in human peripheral leukocytes assessed as inhibition of calcium ionophore A23187-induced LTB4 production after 10 mins by ELISA in presence of 0.5% human serum albumin2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID722473Inhibition of mPGES1 (unknown origin) using PGH2 as substrate incubated for 30 mins prior to substrate addition by PGH2-coupled spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fragment-based discovery of novel and selective mPGES-1 inhibitors Part 1: identification of sulfonamido-1,2,3-triazole-4,5-dicarboxylic acid.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID412948Inhibition of ovine COX12008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1272815Inhibition of PGES-1 in IL-1beta stimulated human A549 cell microsomes using PGH2 as substrate assessed as suppression of PGE2 formation preincubated for 15 mins followed by substrate addition by reversed phase-HPLC analysis2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors.
AID1625259Inhibition of recombinant rat mPGES12016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions.
AID700862Inhibition of 5-lipoxygenase-mediated 5(S)-H(p)ETE formation in fMLP-stimulated human PMNL incubated 10 mins prior to fMLP challenge2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.
AID1327124Antiinflammatory activity in FLAP-devoid/5-LO expressing HEK293 cells assessed as inhibition of A23187-stimulated 5-LO product formation at 0.3 uM preincubated for 15 mins followed by A2318/arachidonic acid addition by RP-HPLC analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
AID7150The compound was tested for inhibition of isolated 5-lipoxygenase1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID721255Inhibition of rat mPGES-1 transfected in CHOK1 cells using [3H]PGH2 as substrate2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel benzoxazole inhibitors of mPGES-1.
AID717377Inhibition of microsomal PGES1 using PGH2 as substrate by RP-HPLC method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of novel mPGES-1 inhibitors through screening of a chemical library.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID700864Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.
AID413196Inhibition of 5-LO in PMNL cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1759205Inhibition of mPGES-1 activity in IL-1beta stimulated human A549 cells by cell-free assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E
AID453621Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane at 10 uM assessed as enzyme residual activity by PGE2 formation assay relative to untreated control2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID465970Inhibition of human mPGES12010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
AID1304632Inhibition of mPGES-1 in microsomes of IL1-beta induced human A549 cells assessed as PGE2 formation by measuring enzyme residual activity at 1 mM preincubated for 15 mins followed by addition of PGH2 as substrate measured after 1 min by RP-HPLC method rel2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID596923Inhibition of rat microsomal PGES12011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E₂ synthase-1 (mPGES-1).
AID1155608Antiinflammatory activity in zymosan-induced peritonitis CD1 mouse model assessed as suppression of neutrophil infiltration at 1 mg/kg, ip administered 30 mins before challenge measured 4 hrs post zymosan challenge relative to control2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase.
AID1201316Inhibition of mPGES1 in IL-1beta stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 synthase activity after 15 mins using PGH2 substrate by RP-HPLC method2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID632048Inhibition of FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production preincubated for 11 hrs by ELISA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID637533Inhibition of human recombinant mPGES-1 in assessed as conversion of PGH2 into PGE2 at 20 degC after 5 mins by HPLC-UV analysis2012European journal of medicinal chemistry, Feb, Volume: 48Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
AID405527Inhibition of human recombinant mPGES1 expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID1201319Inhibition of 12-LOX in human blood PMNL assessed as remaining activity by measuring 12-HETE synthesis at 10 uM2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID665660Inhibition of FLAP in A23187-stimulated human neutrophils assessed as 5-LO product formation preincubated for 15 mins measured after 10 mins2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID632155Inhibition of FLAP in human peripheral leukocytes assessed as inhibition of calcium ionophore A23187-induced LTB4 production after 5 mins by ELISA in absence of human serum albumin2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID1201317Inhibition of 15-LOX-1 in human blood PMNL assessed as remaining activity by measuring 15-HETE synthesis at 10 uM2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID465971Inhibition of FLAP2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
AID1057575Antiinflammatory activity in CD-1 mouse peritonitis model assessed as reduction in neutrophil infiltration at 1 mg/kg, ip administered 30 mins prior to zymosan-challenge measured after 4 hrs by spectrophotometry relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID178501Compound was tested for in vivo inhibition against rat antigen bronchospasm1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID453624Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2 at 30 uM2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID721254Inhibition of FLAP (unknown origin)2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel benzoxazole inhibitors of mPGES-1.
AID676829Inhibition of mPGES-1-mediated PGE2 formation in IL-1beta-stimulated human A549 cells at 10 uM preincubated for 10 mins measured after 1 min by RP-HPLC analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1.
AID632047Inhibition of FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production preincubated for 5 hrs by ELISA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID1484243Inhibition of human A549 cell microsomal membrane-derived mPGES-1 assessed as reduction in conversion of PGH2 to PGE2 preincubated for 15 mins followed by PGH2 addition measured after 1 min by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID1327126Inhibition of FLAP in human neutrophils assessed as suppression of A23187-stimulated 5-LO product formation using arachidonic acid as substrate measured as residual activity at 10 uM preincubated for 15 mins followed by A23187/arachidonic acid addition af2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
AID1484242Inhibition of 5-LO in human peripheral blood neutrophils using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins in presence of Ca2+ ionophore A23187 by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID160512Compound was tested for in vitro inhibition against human PMNL1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1057567Inhibition of 5-lipoxygenase in A23187-stimulated human polymorphonuclear leukocytes using arachidonic acid as substrate incubated 15 mins prior to substrate addition measured after 10 mins by HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID703844Inhibition of 5-lipoxygenase in A23187-stimulated human neutrophils assessed as inhibition of enzyme product formation by RP-HPLC analysis2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
AID1411795Inhibition of FLAP in human leukocytes assessed as decrease in ionophore A23187-induced LT biosynthesis after 10 mins2018MedChemComm, Feb-01, Volume: 9, Issue:2
Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
AID412944Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation by cell-free assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID632158Inhibition of FLAP in human peripheral leukocytes assessed as inhibition of calcium ionophore A23187-induced LTB4 production after 3 hr by ELISA in presence of 0.5% human serum albumin2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID453628Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2 at 0.3 uM2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID405526Inhibition of rat mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID453622Inhibition of ovine COX1 assessed as residual enzyme activity at 10 uM relative to untreated control2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID240920Inhibitory concentration against human prostaglandin E2 synthase (mPGES-1)2005Bioorganic & medicinal chemistry letters, Jul-15, Volume: 15, Issue:14
Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.
AID722472Inhibition of rat mPGES1 expressed in CHOK21 cells using [3H]PGH2 as substrate by radio-HPLC analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fragment-based discovery of novel and selective mPGES-1 inhibitors Part 1: identification of sulfonamido-1,2,3-triazole-4,5-dicarboxylic acid.
AID1357417Inhibition of ovine COX1 using arachidonic acid as substrate pretreated for 5 mins followed by substrate addition and measured after 5 mins by HPLC analysis2018European journal of medicinal chemistry, Jun-10, Volume: 153Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.
AID1057573Antiinflammatory activity in CD-1 mouse peritonitis model assessed as reduction in myeloperoxidase activity at 1 mg/kg, ip administered 30 mins prior to zymosan-challenge measured after 4 hrs by spectrophotometry relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID420630Inhibition of ovine COX1 assessed as residual enzyme activity at 30 uM preincubated for 5 mins by measuring 12-HHT level using HPLC method relative to control2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID412941Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation at 10 uM by cell-free assay relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1395141Inhibition of recombinant human 5-LO expressed in Escherichia coli BL21 incubated for 15 mins prior to prewarming for 30 secs followed by CaCl2+ and arachidonic acid addition and measured after 10 mins by RP-HPLC analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Identification of multi-target inhibitors of leukotriene and prostaglandin E
AID413197Inhibition of mPGES1 in human A549 cells assessed as inhibition of IL-1-beta-induced PGE2 formation at 33 uM by cell-intact assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID453630Reversible inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2 at 3 uM measured after 10 fold compound dilution2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID7092The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID405532Inhibition of mPGES1 in LPS-stimulated human whole blood at 100 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID1153839Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.
AID632156Inhibition of FLAP in human peripheral leukocytes assessed as inhibition of calcium ionophore A23187-induced LTB4 production after 1 hr by ELISA in absence of human serum albumin2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID667532Inhibition of mPGES1 in rat microsomal membranes assessed as inhibition of PGE2 production at 10 uM after 40 seconds by enzyme immunoassay2012European journal of medicinal chemistry, Aug, Volume: 54Design and synthesis of a second series of triazole-based compounds as potent dual mPGES-1 and 5-lipoxygenase inhibitors.
AID1153838Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells at 10 uM preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis relative to control2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.
AID101440The compound was tested for inhibition LTC4 synthase from whole cells in rat1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID703840Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
AID1484241Inhibition of human recombinant 5-LO expressed in Escherichia coli MV1190 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID598678Inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli BL21 assessed as enzyme product formation using arachidonic acid as substrate at 1 uM after 10 mins by RP-HPLC analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1.
AID6734The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS]1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID1759203Inhibition of mPGES-1 activity in IL-1beta stimulated human A549 cells microsomes assessed as reduction in PGE2 production preincubated for 15 mins followed by PGH2 addition and measured after 1 mins by EIA2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E
AID453629Inhibition of mPGES1 in IL1-beta induced human A549 cell microsomal membrane assessed as blockade of conversion of PGH2 to PGE2 at 3 uM2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID420631Inhibition of human recombinant COX2 assessed as residual activity at 30 uM preincubated for 5 mins by measuring 12-HHT level using HPLC method relative to control2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID413198Inhibition of mPGES12008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1139567Inhibition of human mPGES1 from human A549 cells assessed as PGE2 at 10 uM after 15 mins by HPLC2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID700994Inhibition of human recombinant 5-lipoxygenase-mediated product formation from arachidonic acid assessed as remaining activity at 1 uM after 5 to 10 mins by HPLC analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.
AID1357415Inhibition of mPGES1 in human A549 cell microsomes2018European journal of medicinal chemistry, Jun-10, Volume: 153Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.
AID1057565Inhibition of mPGES-1 from human A549 cell microsomal membranes using PGH2 as substrate incubated 15 mins prior to substrate addition measured after 1 min by RP-HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID1057577Antiinflammatory activity in CD-1 mouse peritonitis model assessed as reduction in vascular permeability at 1 mg/kg, ip administered 30 mins prior to zymosan-challenge measured after 4 hrs relative to vehicle-treated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID7206Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
AID1357408Inhibition of mPGES1 in human A549 cell microsomal membrane using pGH2 as substrate pretreated for 15 mins followed by substrate addition and measured after 1 min by RP-HPLC method2018European journal of medicinal chemistry, Jun-10, Volume: 153Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.
AID126629Compound was tested for in vivo inhibition against squirrel monkey antigen bronchospasm at 1 mg/kg1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1327123Inhibition of FLAP (unknown origin) expressed in HEK293 cells co-expressing 5-LO assessed as suppression of A23187-stimulated 5-LO product formation at 0.3 uM using arachidonic acid as substrate preincubated for 15 mins followed by A23187/substrate additi2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1478503Inhibition of mPGES-1 in interleukin-1 beta-stimulated human A549 cells microsomal membranes assessed as reduction in conversion of PGH2 to PGE2 pre-incubated for 15 mins followed by PGH2 substrate addition measured after 1 min by RP-HPLC method
AID1155610Antiinflammatory activity in zymosan-induced peritonitis CD1 mouse model assessed as suppression of MPO activity at 1 mg/kg, ip administered 30 mins before challenge measured 4 hrs post zymosan challenge relative to control2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase.
AID637534Inhibition of human recombinant mPGES-1 in assessed as conversion of PGH2 into PGE2 at 10 uM at 20 degC after 5 mins by HPLC-UV analysis in presence of 0.1% Triton X-1002012European journal of medicinal chemistry, Feb, Volume: 48Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1.
AID372033Inhibition of A23817-induced translocation of 5-lipoxygenase from cytosol to perinuclear region in human neutrophils at 0.1 uM to 10 uM by Western blot2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID1272816Inhibition of PGES-1 in IL-1beta stimulated human A549 cell microsomes using PGH2 as substrate assessed as suppression of PGE2 formation at 10 uM preincubated for 15 mins followed by substrate addition by reversed phase-HPLC analysis2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors.
AID453623Inhibition of human recombinant COX2 assessed as residual enzyme activity at 10 uM relative to untreated control2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
AID1902162Inhibition of recombinant LTC4S (unknown origin) expressed in COS cells2022European journal of medicinal chemistry, Mar-05, Volume: 231Novel potent benzimidazole-based microsomal prostaglandin E
AID1327125Inhibition of FLAP in human neutrophils assessed as suppression of A23187-stimulated 5-LO product formation using arachidonic acid as substrate measured as residual activity at 1 uM preincubated for 15 mins followed by A23187/arachidonic acid addition aft2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
AID226853Inhibitory activity against LT biosynthesis; IC50 = 3-5 nM1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID420632Inhibition of 5-lipoxygenase in bovine polymorphonuclear leucocytes assessed as formation of LTB4 by HPLC method2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
AID7212Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1448334Inhibition of COX-mediated PGD2/PGE2 production in arachidonic acid-stimulated RBL1 cells at 10 nM preincubated for 2 hrs followed by A23187 induction for 15 mins by LC/MS/MS analysis relative to control2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
AID1448335Inhibition of 5-LOX-mediated LTB4 production in arachidonic acid-stimulated RBL1 cells at 10 nM preincubated for 2 hrs followed by A23187 induction for 15 mins by LC/MS/MS analysis relative to control2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
AID413191Inhibition of human recombinant COX22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID89430The compound was tested for inhibitory activity against Leukotriene synthesis in human monocytes1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID1448332Induction of microtubule stabilization in human QBI293 cells assessed as increase in acetylated tubulin levels at 10 uM after 4 hrs by ELISA relative to control2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases.
AID405531Inhibition of FLAP2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID1239703Inhibition of mPGES-1 in IL-1beta-stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 formation incubated for 15 mins using PGH2 substrate by RP-HPLC method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Discovery of novel, non-acidic mPGES-1 inhibitors by virtual screening with a multistep protocol.
AID1674981Protection against amyloid beta oligomer-induced cytotoxicity in human SH-SY5Y cells expressing wild-type Tau assessed as cell viability at 10 uM by MTT assay2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Discovery of biphenyl pyrazole scaffold for neurodegenerative diseases: A novel class of acetylcholinesterase-centered multitargeted ligands.
AID465969Inhibition of rat mPGES12010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
AID620116Inhibition of microsomal PGES2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Novel human mPGES-1 inhibitors identified through structure-based virtual screening.
AID1803987SARS-CoV-2 CPE assay from Article 10.1101/2020.07.17.207019: \\Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.\\2020bioRxiv : the preprint server for biology, Aug-11Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID18039863CLpro enzyme assay from Article 10.1101/2020.07.17.207019: \\Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.\\2020bioRxiv : the preprint server for biology, Aug-11Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
AID1800288Microsomal prostaglandin E synthase-1 activity assay from Article 10.1111/cbdd.12280: \\Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1.\\2014Chemical biology & drug design, Jun, Volume: 83, Issue:6
Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 , cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1.
AID1346759Mouse Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2001The Biochemical journal, Jan-15, Volume: 353, Issue:Pt 2
Peroxisomal bifunctional enzyme binds and activates the activation function-1 region of the peroxisome proliferator-activated receptor alpha.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (464)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.43)18.7374
1990's175 (37.72)18.2507
2000's138 (29.74)29.6817
2010's132 (28.45)24.3611
2020's17 (3.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index6.19 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.82%)5.53%
Reviews14 (2.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other467 (96.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]